Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.94
SGYP's Cash to Debt is ranked lower than
57% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. SGYP: 0.94 )
Ranked among companies with meaningful Cash to Debt only.
SGYP' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 10000.00 Max: No Debt
Current: 0.94
F-Score: 2
Z-Score: -3.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA (%) -77.93
SGYP's ROA (%) is ranked lower than
96% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. SGYP: -77.93 )
Ranked among companies with meaningful ROA (%) only.
SGYP' s ROA (%) Range Over the Past 10 Years
Min: -6858.53  Med: -154.23 Max: -66.95
Current: -77.93
-6858.53
-66.95
ROC (Joel Greenblatt) (%) -17038.16
SGYP's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. SGYP: -17038.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGYP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -423053.33  Med: -169122.22 Max: -15143.46
Current: -17038.16
-423053.33
-15143.46
EBITDA Growth (3Y)(%) 48.90
SGYP's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. SGYP: 48.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGYP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 35.90 Max: 122.4
Current: 48.9
0
122.4
EPS Growth (3Y)(%) 49.50
SGYP's EPS Growth (3Y)(%) is ranked higher than
91% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. SGYP: 49.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGYP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 35.90 Max: 126.2
Current: 49.5
0
126.2
» SGYP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SGYP Guru Trades in Q1 2015

John Paulson 2,095,600 sh (New)
Paul Tudor Jones 11,517 sh (New)
Jim Simons Sold Out
» More
Q2 2015

SGYP Guru Trades in Q2 2015

Louis Moore Bacon 325,000 sh (New)
Paul Tudor Jones 55,415 sh (+381.16%)
John Paulson 5,781,500 sh (+175.89%)
» More
Q3 2015

SGYP Guru Trades in Q3 2015

Steven Cohen 256,208 sh (New)
John Paulson 9,000,000 sh (+55.67%)
Paul Tudor Jones 42,506 sh (-23.30%)
Louis Moore Bacon 225,000 sh (-30.77%)
» More
Q4 2015

SGYP Guru Trades in Q4 2015

Jim Simons 397,600 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Current Ratio 7.25
SGYP's Current Ratio is ranked higher than
87% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. SGYP: 7.25 )
Ranked among companies with meaningful Current Ratio only.
SGYP' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.21 Max: 11.88
Current: 7.25
0.04
11.88
Quick Ratio 7.25
SGYP's Quick Ratio is ranked higher than
88% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. SGYP: 7.25 )
Ranked among companies with meaningful Quick Ratio only.
SGYP' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.21 Max: 11.88
Current: 7.25
0.04
11.88

Valuation & Return

vs
industry
vs
history
Price/Graham Number 1.38
SGYP's Price/Graham Number is ranked higher than
70% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. SGYP: 1.38 )
Ranked among companies with meaningful Price/Graham Number only.
SGYP' s Price/Graham Number Range Over the Past 10 Years
Min: 1.8  Med: 4.77 Max: 9.13
Current: 1.38
1.8
9.13
Earnings Yield (Greenblatt) (%) -25.83
SGYP's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SGYP: -25.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGYP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -36.2  Med: 0.00 Max: 0
Current: -25.83
-36.2
0

More Statistics

EPS $ -1.17
Beta1.65
Short Percentage of Float27.84%
52-Week Range $2.84 - 10.15
Shares Outstanding(Mil)113.67

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 13 57
EPS($) -1.02 -0.96 -0.69 -0.35
EPS without NRI($) -1.02 -0.96 -0.69 -0.35

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S90.Germany,
Synergy Pharmaceuticals Inc was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. The Company is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by constipation symptoms but a majority of these patients report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C is characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. The Company's main competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., and Takeda. The Company is subject to various environmental, health and safety regulations including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials.
» More Articles for SGYP

Headlines

Articles On GuruFocus.com
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 

More From Other Websites
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) Analyst Coverage; NDA filed with the FDA Feb 09 2016
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 02 2016
Synergy Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference Feb 02 2016
Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic... Jan 29 2016
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 29 2016
Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic... Jan 29 2016
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits Jan 22 2016
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 21 2016
3 Biotech Stocks Under $10 to Trade for Big Gains Jan 15 2016
Here's What the Real Money Team Would Buy With Powerball Winnings Jan 13 2016
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 11 2016
Synergy Pharmaceuticals Announces Positive Trial Results with Dolcanatide in Patients with... Jan 11 2016
Synergy Pharmaceuticals Announces Positive Trial Results with Dolcanatide in Patients with... Jan 11 2016
Trending Now: SGYP Jan 10 2016
Synergy's Looming FDA Filing Makes It Pharma of the Month Jan 05 2016
Five Cheap Healthcare Stocks Poised to Explode Dec 20 2015
Synergy Pharma downgraded by Citigroup Dec 18 2015
4 Biotech Stocks Under $10 to Trade for Big Breakouts Dec 13 2015
SYNERGY PHARMACEUTICALS, INC. Financials Dec 08 2015
Elite Hedge Funds Make Big Moves In These 3 Healthcare Stocks Dec 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK